About us

Acesis BioMed is a Colorado (US) & London (UK) based biomedical company developing a platform of oral drug candidates for metabolic and endocrine disorders, initially focusing on male hypogonadism treatment (low T).

  • Hypogonadism indication provides Acesis with a target market of $3bn - $4bn
  • Co-morbidities of low T such as obesity, fatty liver disease, prediabetes, cachexia offer additional target addressable markets
  • The company’s proprietary “first-in-class” T peptide modulator provides a safer solution to the existing Testosterone Replacement Therapy (TRT)*
  • Upon regulatory approval, we aim to become the standard of care for the treatment of male hypogonadism globally

* based on our preclinical data

About

historical Funding

  • Dr Vassilios Papadopoulos has received more than $12 million research funding from multiple sources to support the groundwork leading to the understanding of the mechanism underlying steroidogenesis, its regulation & the identification of a novel molecular therapeutic target of T restoration
  • The discovery of peptides modulating the activity of this novel target and T synthesis led to the IP developed by Dr Papadopoulos’ research team which forms Acesis’ core asset
  • Acesis (formerly Iaso BioMed Inc.) supported a research project for the development of T modulating peptides in Dr Papadopoulos’ lab at the Research Institute of McGill University Health Centre
read about our Programs >
Vassilios Papadopoulos